Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs

Study identification

• EU PAS number:
  EUPAS13904
• Study ID:
  19186
• Official title and acronym:
  Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  The study is intended to monitor the occurrence of thyroid neoplasm and pancreatic cancers with weekly exenatide. Anonymised electronic health care records will be used to monitor the weekly exenatide users and compare them to patients using other types of medication
• Study status:
  Ongoing

Research institutions and networks

Institutions

Clinical Practice Research Datalink (CPRD)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 21/10/2013

Actual: 07/11/2013

Study start date

Planned: 01/07/2011

Actual: 01/07/2011

Data analysis start date

Planned: 10/11/2013

Actual: 10/11/2013

Date of final study report

Planned: 31/12/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

D5551N00007